A study in JAMA Network Open evaluated a telemedicine-supported home injection model for breast cancer patients receiving injectable gonadotropin-releasing hormone agonist therapy. The research reported that shifting treatment administration from clinic to home could reduce the practical burden associated with repeated visits. The findings add evidence to the growing push for hybrid care delivery models, where remote monitoring and virtual support help maintain treatment continuity. For oncology programs and device/diagnostics vendors, the work highlights how care logistics can become an operational differentiator as much as the drug itself.